Kinnate Biopharma (NASDAQ:KNTE – Get Rating) had its price objective trimmed by Wedbush from $29.00 to $25.00 in a report released on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.
Separately, Stifel Nicolaus dropped their price target on shares of Kinnate Biopharma from $11.00 to $8.00 and set a hold rating on the stock in a research report on Thursday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $25.00.
Kinnate Biopharma Stock Down 0.7 %
KNTE stock opened at $5.42 on Thursday. The company has a 50-day simple moving average of $6.17 and a 200 day simple moving average of $8.14. Kinnate Biopharma has a fifty-two week low of $3.30 and a fifty-two week high of $15.86.
Institutional Trading of Kinnate Biopharma
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Alliancebernstein L.P. acquired a new stake in Kinnate Biopharma during the 4th quarter worth about $81,000. Jane Street Group LLC acquired a new stake in Kinnate Biopharma during the 4th quarter worth about $77,000. SVB Financial Group acquired a new stake in Kinnate Biopharma during the 4th quarter worth about $143,000. Squarepoint Ops LLC acquired a new stake in Kinnate Biopharma during the 4th quarter worth about $153,000. Finally, Marshall Wace LLP raised its holdings in Kinnate Biopharma by 30.5% during the 4th quarter. Marshall Wace LLP now owns 14,944 shares of the company’s stock worth $91,000 after buying an additional 3,492 shares during the period. Institutional investors and hedge funds own 98.68% of the company’s stock.
Kinnate Biopharma Company Profile
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.